The Alpha-1 Foundation is dedicated to providing leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 antitrypsin deficiency.
This award is named after John W. Walsh, who dedicated his life’s work to finding a cure for Alpha-1 Antitrypsin Deficiency. Walsh and two others, all with Alpha-1 themselves, founded both the Alpha-1 Foundation and AlphaNet in 1995. Walsh’s leadership and passion have helped to shape the Alpha-1 Foundation into a successful organization and he is responsible for many of the Foundation’s accomplishments over more than two decades.
All proposals must be hypothesis-testing, or generate new information on topics relevant to the funding opportunity. Projects must provide sufficient preliminary data to justify the Foundation’s support. A grant supported by this funding opportunity is intended to be three years in duration; however, funding for the second and third years will be approved based upon documentation of progress.
The Alpha-1 Foundation intends to commit up to a total of $225,000 over three (3) years to fund one (1) grant. The award pursuant to this funding opportunity is contingent upon the receipt of a meritorious application. The grant will be awarded to the principle investigator’s institution. If multiple study sites are required, they must be administered as sub-contracts. The Foundation will only contract with the primary site.
Eligible candidates for this award must have a clinical or research doctorate (including Ph.D., M.D., D.O., D.C., N.D., D.D.S., D.M.D., D.V.M., Sc.D., D.N.S., Pharm.D. or an equivalent doctoral degree).
See the Alpha-1 website for complete program guidelines and proposal instructions.